ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Objectives:Fraciton of exhaled nitric oxide (FeNO) and blood eosinophil counts (b-EOS) are recognized as the predictors for effectiveness of biologics to ?ype 2 severe asthma. Previously, we reported asthma exacerbation (AE) was most frequent in severe asthma patients with the high FeNO/low b-EOS among four subgroups of those who were treated with biologics except for dupilumab or no biologics and divided by FeNO and b-EOS (Front Pharmacol. 2022;13:836635). Here, we further examined the frequency of acute exacerbation in severe asthma patients receiving omalizumab, mepolizumab, benralizumab, or dupilumab.

Methods:One hundred twenty one severe asthma patients were classified into 4 four subgroups based on FeNO (27ppb) and b-EOS (265/?l). Annual frequency of AEs and prevalence of four biologics was evaluated in the 4 subgroups.

Results:The high FeNO/high b-EOS, high FeNO/low b-EOS, low FeNO/high b-EOS, and low FeNO/low b-EOS subgroup had 32, 30, 28, and 31of patients, respectively.There was no significant difference in the number of AEs between the four groups (p=0.054).

Biologic use rates differed among the four groups?p=0.02?, showing a higher rate of dupilumab use (33%) in the high FeNO/low b-EOS.

Conclusion:Dupilumab use might contribute to the reduction of AEs observed with the high FeNO/low b-EOS subgroup.

Abstract

#{title}